Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Comprehensive Overview of Coagulation Factor V and Congenital Factor V Deficiency Publisher Pubmed



Tabibian S1 ; Shiravand Y2 ; Shams M3 ; Safa M1 ; Gholami MS1 ; Heydari F1 ; Ahmadi A4 ; Rashidpanah J5 ; Dorgalaleh A1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Hemmat Highway, 14496, Tehran, 14535, Iran
  2. 2. Department of Hematology and Blood Transfusion, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Medical Laboratory, Faculty of Paramedical Sciences, Babol University of Medical Sciences, Babol, Iran
  4. 4. Cellular and Molecular Research Center, Research Institute for Health Development, Department of Molecular Medicine and Genetics, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
  5. 5. Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran

Source: Seminars in Thrombosis and Hemostasis Published:2019


Abstract

Coagulation factor (F) V is a glycoprotein that plays an essential role in the formation of the prothrombinase complex, which is critical for progressing clot formation. FV deficiency is a rare bleeding disorder with an estimated incidence of one per 1 million in the general population. The disorder is manifested with a wide array of clinical bleeding events. The most common bleeding features of FV deficiency are mucosal bleedings. Life-threatening manifestations are rarely seen in this disorder. FV deficiency is diagnosed using routine coagulation tests and FV activity assay. A wide spectrum of mutations including missense, nonsense, and frameshift is observed throughout the F5 gene. Although fresh frozen plasma is the dominant therapeutic choice, a newly introduced plasma-derived FV concentrate was found effective in in vitro correction of prothrombin time, activated partial thromboplastin time, and thrombin generation parameters in severe FV deficiency and should provide more targeted treatment for patients with FV deficiency in the future. © 2019 by Thieme Medical Publishers, Inc.